$AGN (Allergan plc)

$AGN {{ '2015-09-11T15:38:54+0000' | timeago}} • Announcement

$AGN reached to an agreement with Apexus yesterday, where the drug LILETTA will be made available at a discounted per unit price to all health clinics and organizations participating in the 340B Prime Vendor Program (PVP). It also expands IUD accessibility to millions of underserved women in the US who are unable to afford one.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

$AGN {{ '2017-08-03T19:43:47+0000' | timeago}} • Announcement

"With our strong first half performance and solid outlook for the remainder of the year, we are raising our full-year guidance,” said CEO Brent Saunders. For FY17, $AGN expects sales to be $15.85-16.05Bil, up from the prior estimate of $15.8-16.0Bil. GAAP loss per share is expected to be $10.80-11.20 versus the previous range of $9.70-10.20.

$AGN {{ '2017-08-03T18:43:48+0000' | timeago}} • Announcement

$AGN, which owns 9.9% stake in $TEVA, reported a wider loss in 2Q17, hurt by the loss of patent exclusivity and lower revenues from certain drugs. Net loss attributable to ordinary shareholders was $796MM or $2.37 per share compared to $571MM or $1.44 per share a year ago. However, revenue rose 9% to $4.01Bil and adjusted EPS increased 20% to $4.02.

$AGN {{ '2017-08-03T14:32:45+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q2 2017 Highlights

$AGN {{ '2017-08-02T17:05:08+0000' | timeago}} • Announcement

$AGN's BoD declared 3Q17 cash dividend of $0.70 per ordinary share. The dividend will be paid on Sept. 15, 2017 to shareholders of record at the close of business on Aug. 18, 2017.

$AMGN {{ '2017-07-31T13:27:43+0000' | timeago}} • Announcement

$AMGN and $AGN announced the submission of a Biologics License Application (BLA) to the FDA for ABP 980, a biosimilar candidate to Herceptin (trastuzumab). These two companies are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$AMGN {{ '2017-06-07T14:18:46+0000' | timeago}} • Announcement

$AMGN and $AGN said that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab), on July 13, 2017. Bevacizumab is medication used to treat types of cancers and specific eye disease.

$AGN {{ '2017-06-07T14:08:57+0000' | timeago}} • Announcement

$AGN's subsidiary Allergan Sales LLC agreed to buy privately-held Keller Medical, a medical device company and developer of the Keller Funnel. The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during breast augmentation or reconstruction procedures.

$AGN {{ '2017-05-24T14:41:46+0000' | timeago}} • Announcement

$AGN announced the early tender results for tender offers commenced by its subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, and Allergan Inc., each as co-offeror with $AGN's subsidiary Warner Chilcott Ltd., to purchase for cash certain debt securities issued by the entities.

$AGN {{ '2017-05-23T12:27:35+0000' | timeago}} • Announcement

$AGN began an offering of senior unsecured notes in multiple tranches in a registered public offering. The notes will be issued by its indirect subsidiary Allergan Funding SCS and guaranteed by its indirect subsidiaries Warner Chilcott, Allergan Capital and Allergan Finance.

$AGN {{ '2017-05-09T19:02:30+0000' | timeago}} • Webcast

On M&A, $AGN commented that the company is in a strong position currently with no need to do large M&A, with the caveat that it will always be opportunistic. Additionally, $AGN said that the company's focus is on steppingstones and continuing to advance its own strategy.

$AGN {{ '2017-05-09T18:53:46+0000' | timeago}} • Webcast

$AGN's outlook for 2Q17 is higher and expects revenue in the range of $3.9-4Bil. GM for 2Q17 will be lower than 1Q17, largely due to product mix; full quarter for LifeCell, two quarters of ZELTIQ in 2Q17, which has lower GMs. Additionally, Minastrin is having its first full quarter going generic.

$AGN {{ '2017-05-09T18:45:21+0000' | timeago}} • Webcast

$AGN said that regarding RESTASIS IPR and the federal court case, the company has two matters that are coming up in Aug. The company added that it has the hearing on the IPR, and also has the trial in the court in Texas. $AGN anticipate decisions in both of those in the Nov. to Dec. timeframe.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, August 8 2017 - 12:30pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
MCK (McKesson Corporation)
Thursday, July 27 2017 - 12:30pm
EW (Edwards Lifesciences Corp.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm

AlphaGraphics you may like